- The first results have been announced after Supplementation with hyphae immunomodulatory nutraceutics da terra in users of geriatric residences diagnosed with COVID-19
- Preliminary results effectively show that it has been achieved reduce the expected lethality In this group of risk patients from 24.1% to 1.4%
- More than 88% of the patients who followed the stated protocol did not express associated complications to the COVID-19 and none required admission to ICU (the hospital admission dropped from 27% to 12.3%)
- These results show that the supplementation with nutraceutical developed by Hifas da Terra It could be useful in the adjuvant treatment of patients with COVID-19, especially in the groups most vulnerable to infection
Hifas da Terra (HDT) has announced the preliminary results of the TEST IN GERIATRIC RESIDENCES USERS DIAGNOSTICED WITH COVID-19 in which it is evident that supplementation through Immunomodulatory nutraceutics It can significantly improve the situation of patients most vulnerable to pandemic to decrease lethality and the Complications associated with SARS-COV-2 infection.
The study carried out between April and May 2020 collects the favorable evolution of the health status of 73 users of a geriatric residence in Madrid diagnosed with COVID-19 (PCR and/or serology) that initiated the supplementation protocol, being one of the Population groups with greater vulnerability Before the virus.
In general terms, users of geriatric residences represent a high -risk group since they are elderly, have a weak immune system and are diagnosed with at least three active previous pathologies.
Reduction in lethality of COVID-19 in the elderly
After supplementation with immunomodulating nutraceuticals, the group of patients with an average of 87.2 years of age evidenced The reduction of lethality associated with COVID-19. The rate of expected lethality was reduced from 24% to 1.4%, being the first value the official data of the Ministry of Health From the Government of Spain for the age group of 80-90 years as of April 21, 2020, when the study began.
The reduction is also significant if compared to the rate of Expected mortality In similar age groups, encrypted in 42% by the ministry.
Reduction of the expected lethality rate in high-risk patients diagnosed with COVID-19 in elderly residences after the supplementation protocol with immunomodulating nutraceuticals.
Source: Observational study of 73 elderly patients with COVID-19 supplemented with hyphae immunomodulatory nutraceutics da Terra at the Leganés geriatric medical assistance center (Madrid)
Complications associated with COVID-19
The study results also show that the patients to whom the supplementation was supplied They did not present complications associated, reducing expected hospital admission rates from 27% to 12.3% nationally. If we take as a reference the international studies data, the hospital admission rate reaches 54%.
Intensive Care Unit (UCI)
Despite the severity of infection in the study group, patients who received supplementation and entered They did not get worse. The positive evolution of your diagnostic condition Avoid the need for admission to ICU, whose expected rate for that age group would be 3.7%, also according to the data provided by the Government of Spain.
He Dr. Manuel Soler, doctor and scientific head of the study entitled Mycotherapy could reduce mortality and complications associated with COVID-19 in the elderly of Spanish residences points out that "Preliminary test data have a great clinical significance in the treatment of COVID-19 as it has been carried out in patients exposed to a greater transmission of the virus."
"The impact is even greater if the high rate of Mortality by COVID-19 in the elderly, that in residences he has achieved values close to 70%, as has been published recently, ”says the Dr. Soler.
According to the director of R&D of Hifas da Terra, the Dr. Esteban Sonde, The protocol designed for this essay "It provides molecules with immunomodulatory and anti -inflammatory activity that have proven useful in prevention and container in multiple virus treatments".
"We currently work on a hypothesis of action focused on the immunomodulating action of our nutraceuticals to regulate hyperinflammation and cytokine storm that occur as a result of infection by this coronavirus.", he adds.
Although it is preliminary data, the conclusions on the prevention and slowdown of SARS-COV-2 infection "They could open a complementary route to other medical treatments, especially for other affected residences.". In this sense, the trial could increase their number of patients in the coming months and have new entities and health professionals around the world.
About the protocol carried out in the trial
- A specific protocol was applied with immunomodulatory nutraceutics, vitamins and minerals in 73 resident patients of the Leganés geriatric medical assistance center with 87.2 years on average.
- The patient monitoring and supplementation period was 40 days between April and May 2020.
- The diagnosis for COVID-19 was performed by PCR and/or serology.
- With the fundamental objective of helping the health of this vulnerable collective before the Coronavirus Sars-COV-2 in a period of deep health crisis, it was decided to limit the inclusion of a control group so that no patient was denied the supplementation with nutraceutics of fungal origin.
Hifas da Terra investigates the role of fungi in cancer and neurodegenerative, cardiovascular and autoimmune pathologies.
- Bouza, Emilio, et al. "Outbreak of Covid-19 in A Nursing Home in Madrid." The Journal of Infection (2020).
- Update No. 83. CORONAVIRUS disease (COVID-19). 22.04.2020 (Consolidated data at 9:00 p.m. on 9.04.2020) Situation in Spain
- McMichael, Temet M., et al. "Epidemiology of Covid-19 in A Long-Term Care Facility in King County, Washington." New England Journal of Medicine 382.21 (2020): 2005-2011.
- Sacco, Guillaume, et al. "Covid-19 in Seniors: Findings and Lessons from Mass Screening in A Nursing Home." Maturitas 141 (2020): 46-52.
- Pieter T. M. Van Dijk, Mehr D et als. Comorbidity and 1-YEAR Mortality Risks in Nursing Home Residents. J Am Geriat SOC 2005; 53: 660–665,
- MEHTA, PUJA, et al. "COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression." Lancet (London, England) 395.10229 (2020): 1033.
- Linnakoski, Riikka, et al. "Antiviral Agents from Fungi: Diversity, Mechanisms and Potential Applications." Frontiers in Microbiology 9 (2018): 2325.
- WEISS P, MURDOCH DR. Clinical Course and Mortality Risk of Severe Covid-19. Lancet 2020; 395 (10229): 1014-1015. DOI: 10.1016/S0140-6736 (20) 30633-4.
-
Monahan C, Macdonald J, Lytle A, Apriceno M, Levy Sr. COVID-19 and AGEISM: How Positive and Negative Resparns Impact Older Adults and Society
. Am psychol. 2020 - Savelkoul, H. F. J., W. Chanput, and H. J. Wichers. "Immunomodulatory Effects of Mushroom β-Glucans." Diet, Immunity and inflammation. Woodhead Publishing, 2013. 416-434.